# Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

> **NCT04945707** · PHASE4 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 66 (estimated)

## Conditions studied

- Iron-deficiency
- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04945707
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-26
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04945707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04945707, "Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04945707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*